Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 29, 2017
Pharmacy Choice - News - Generic Drugs - March 29, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 212     Next >>     Go To Page:

3/21/17 - Alexander: Congress Owes Patients and Their Families a Prompt, Bipartisan Reauthorization of FDA User Fees
WASHINGTON, D.C., March 21- Senate health Committee Chairman Lamar Alexander today said Congress owes patients and their families a prompt, bipartisan reauthorization of the Food and Drug Administration medical devices and drug user fees agreements, which are set to expire on Sept. 30. Today, we are here to talk about how we continue funding the FD
3/21/17 - Alexander: Congress Owes Patients, Their Families Prompt, Bipartisan Reauthorization of FDA User Fees
Senate health Committee Chairman Lamar Alexander today said Congress owes patients and their families a prompt, bipartisan reauthorization of the Food and Drug Administration medical devices and drug user fees agreements, which are set to expire on Sept. 30. Today, we are here to talk about how we continue funding the FDA, the agency responsible fo
3/21/17 - Glenmark gets tentative nod from USFDA for Fingolimod capsules [Tehran Times (Iran)]
Drug firm Glenmark Pharmaceuticals USA today said it has got tentative approval from the United States Food and Drug Administration for Fingolimod capsules. "Glenmark Pharmaceuticals USA has been granted tentative approval by the USFDA for Fingolimod capsules, 0.5 mg, the generic version of Gilenya capsules of Novartis Pharmaceuticals Corp," Glenm
3/21/17 - Glenmark Pharma receives approval for Clobetasol Propionate Ointment USP, 0.05% [India Infoline News Service]
Glenmark Pharmaceuticals Inc., USA has been granted final approval by USFDA for Clobetasol Propionate Ointment USP, 0.05%, the generic version of Temovate Ointment, 0.05% of Fougera Pharmaceuticals Inc. Glenmark Pharmaceuticals Inc., USA has been granted final approval by USFDA for Clobetasol Propionate Ointment USP, 0.05%, the generic version of..
3/21/17 - HEARING: #SubHealth to Continue User Fee Hearings, Examining MDUFA
WASHINGTON, DC- The Subcommittee on Health, chaired by Rep. Michael C. Burgess, M.D., announced a hearing for Tuesday, March 28, 2017, at 10:15 a.m. in room 2123 of the Rayburn House Office Building. The Health Subcommittee recently held a hearing examining the Generic Drug User Fee Amendments and the Biosimilar User Fee Act, both of which also exp
3/21/17 - LETTER TO THE EDITOR: Clear the way for biosimilar medicines
That's why my role as grassroots manager at the American Cancer Society Cancer Action Network is more than just a job for me. In South Carolina, House Bill 3438 will give more patients in our state access to cutting-edge biosimilar medicines while protecting patient safety. H.3438 would enable pharmacists in South Carolina to offer their patients a
3/21/17 - Senate Health, Education, Labor and Pensions Committee Hearing
Testimony by Janet Woodcock, Director, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD and Peter Marks, Ph.D, Director, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD and Jeffrey E. Shuren, MD, JD, Director, Center for Devices and Radiological Health, Food and D
3/20/17 - Ajanta Pharma jumps 3% on amalgamation approval [India Infoline News Service]
Ajanta Pharma gained 3.2% in Monday's trade as the company's board of directors approved amalgamation of Gabs Investments with itself. Ajanta Pharma gained 3.2% in Monday's trade as the company's board of directors approved amalgamation of Gabs Investments with itself. Ajanta Pharma on the NSE is currently trading at Rs 1846 per share, and is up by
3/20/17 - Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry 2017
Dublin- Research and Markets has announced the addition of the "Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry 2017" report to their offering. A generic drug is a copy that is the same as a brand-name drug in dosage, safety, strength, how it is taken, quality, performance and intended use. As patents near expiration, manufactu
3/20/17 - Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry 2017 - Research and Markets
Research and Markets has announced the addition of the "Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry 2017" report to their offering. Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry 2017- a comprehensive coverage of the generic drugs market in the United States. Strategies for survival employed by branded
3/20/17 - Analyzing the Global Generics Industry 2017
In recent times there has been a growing focus on the generic drugs industry worldwide. Over the years, the global generic drugs industry has grown strongly owing partly to the fact that the period for patent protection has gotten shorter with major blockbuster drugs losing their patent protection. Furthermore, governments around the world have p
3/20/17 - Authorized Generics Market Scope and Trends Report 2016 - 2024
These are already approved as a New Drug Application by the FDA, only they are promoted via private label. Pfizer's original branded drug Z-pak was approved by the FDA. Before patent expiry of Z-pak, Pfizer allowed Greenstone to sell Z-pak using authorized generic name Azithromycin Pak.
3/20/17 - Bio Farma Set on Launching More Affordable Breast Cancer Drug by 2019 [Sudan Tribune]
Erman said Bio Farma plans to sell the biosimilarbiological products derived from living organisms such as tissues, cells, DNA, and proteinsdrug with prices that are more than 50% lower than the biosimilar breast cancer drug produced by European company Roche, which is worth IDR25 million in one dose. "The breast cancer biosimiar drug is patented
3/20/17 - Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 13634) - Workshop
EVENT: Health and Human Services Department; Food and Drug Administration holds a workshop on "Generic Drug User Fee Amendments of 2012; Regulatory Science Initiatives," focusing on the current status of regulatory science initiatives for generic drugs and an opportunity for public input on research priorities in this area. LOCATION: FDA White Oak
3/20/17 - Lupin launches Generic Minastrin 24 Fe chewable tablets in the US
Release date- 18032017- Mumbai, Baltimore- Pharma Major Lupin Limited announced today the launch of Mibelas 24 Fe having received an approval from the United States Food and Drug Administration earlier. Lupin's Mibelas 24 Fe is the AB rated generic equivalent of Allergan Pharmaceuticals International Limited's Minastrin 24 Fe Tablets.
3/20/17 - Studies from M. Radin and Co-Researchers in the Area of Inflammatory Bowel Disease Reported (Infliximab Biosimilars in the Treatment of Inflammatory...
By a News Reporter-Staff News Editor at Clinical Trials Week A new study on Digestive System Diseases and Conditions- Inflammatory Bowel Disease is now available. According to news reporting originating in Turin, Italy, by NewsRx journalists, research stated, "Biological therapies represent a fundamental innovation for the management of inflammat
3/20/17 - Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Launches Minastrin Generic In The United States
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has unveiled the authorized generic version of Minastrin, an oral contraceptive that is combined with progestin/estrogen. This now brings Teva's oral contraceptive portfolio to over 50 ensuring that approximately 50% of prescriptions for oral contraceptives in the United States are a product of
3/20/17 - Update on Mohali Facility
Release date- 18032017- Mumbai, India- Sun Pharmaceutical Industries Ltd was informed by the US FDA yesterday, that it will lift the Import Alert imposed on the Mohali manufacturing facility and remove the facility from the Official Action Initiated status. This proposed action will clear the path for Sun Pharma to supply approved products from the
3/20/17 - UPSHER-SMITH ENTERS AGREEMENT TO EXPAND MARKETING AND DISTRIBUTIONOF GENERIC PRODUCTS FOR U.S. MARKET
Release date- 17032017- Maple Grove, MN- Upsher-Smith Laboratories, Inc. today announced that it has entered into an exclusive agreement with an emerging pharmaceutical company to market and distribute three generic products. Under the terms of the agreement, the partner will develop, manufacture and supply the products exclusively for Upsher-Smith
3/17/17 - 5 Biotech Companies Set for Major Breakouts in 2017
There's nothing more potentially rewarding right now than a visionary biotech company, poised for explosive gains, on the basis of a ground-breaking drug, medical device or procedure. Biotechs worth a look in the markets, include: Cara Therapeutics, Inc., Clovis Oncology, Inc., Biogen Inc., Celgene Corporation, Mylan N.V. amongst others. Amgen is t
3/17/17 - 5 Biotech Companies To Watch In 2017
There "s nothing more potentially rewarding right now than a visionary biotech company poised for explosive gains on the basis of a ground-breaking drug, medical device or procedure. Large-cap or small-cap, this is the definitive year of biotech, and these five picks are all set for big things in 2017- with momentous catalysts that promise massive
3/17/17 - American-made biosimilars a differentiator in US market, Coherus [Sudan Tribune]
US patients and physicians favour domestically-made biosimilars according to Coherus Biosciences. Take AbbVies Humira, for example: over 30 companies are developing a biosimilar version of it, chasing a market worth over $16 bn annually, $10.4 bn of which comes from the US. But in a results earning call this week, Coherus Biosciences CEO Denny Lanf
3/17/17 - BIOCAD: The first ever biosimilar of interferon beta-1a approved in Russia
By a News Reporter-Staff News Editor at Drug Week The Ministry of Health of the Russian Federation has awarded Biocad marketing authorization for its interferon beta-1a biosimilar, a knockoff of Biogen's Rebif that is a key component in treatment of relapsing-remitting multiple sclerosis and included in all international recommendations and...
3/17/17 - Breckenridge Pharmaceutical, Inc. Announces Launch of Desvenlafaxine XR Tablets generic for Pristiq
By a News Reporter-Staff News Editor at Drug Week- Breckenridge Pharmaceutical, Inc. announced the launch of desvenlafaxine succinate extended-release tablets 50 mg and 100 mg, a generic version of Pristiq by Pfizer Inc. The ANDA was filed as a Paragraph IV on the first-to-file date and will share 180- day exclusivity with other ANDA first fil
3/17/17 - Generic Drugs to Slow Growth of Antifungal Market [Daily News Egypt]
-New proprietary research by BCC Research predicts that new and innovative antifungal drugs in development, along with a growing number of people with weakened immune systems and FDA fast-track provisions, are aiding growth in the global market for antifungal drugs. "BCC Research predicts that region and North America to account for 24.9% and 36.9
Articles(s): 1 - 25 of 212     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415